Amanta Healthcare Limited IPO Details Issue Price, Date, News, Allotment Status, GMP Today, Link, Updates

Amanta Healthcare Limited IPO Company Profile:

Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing, and marketing a wide range of sterile liquid products. The company specializes in parenteral solutions using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies, with a portfolio comprising large volume parenterals (LVPs) and small volume parenterals (SVPs) across six therapeutic segments, including IV fluids, formulations, diluents, ophthalmic, respiratory care, and irrigation solutions. It also manufactures medical devices such as irrigation products, first-aid solutions, and eye lubricants. Its state-of-the-art manufacturing facility at Hariyala, District Kheda, Gujarat, houses four LVP lines—two ABFS and two ISBM SteriPort lines—and three SVP lines, including two ABFS and one conventional filling line, supported by dedicated Formulation & Development and Quality Control laboratories.

Amanta Healthcare Limited IPO Details:

Amanta Healthcare Limited IPO Strengths:

• The company manufactures a diverse generic product portfolio of more than 45 products, which are marketed under its own brands in the Indian market through a strong network of over 320 distributors and stockists. In addition to its domestic presence, the company exports its products to multiple international markets, including Africa, Latin America, the United Kingdom, and other regions across the globe.
• It offers a wide range of closure systems, including nipple head, twist-off, luer-lock, and screw types, with container fill volumes ranging from 2 ml to 1,000 ml. Its dedicated formulation and development operations enable the creation of new formulations and the modification or improvement of existing ones, supporting both the company’s own brands and product-partnering businesses.
• The company achieved capacity utilization of 96% as of March 31, 2025, compared to 91% and 87% as of March 31, 2024 and March 31, 2023, reflecting consistent operational efficiency improvement.
• The company’s manufacturing facility is certified for Good Manufacturing Practices (GMP) by the Food & Drugs Control Administration, Gujarat, in accordance with World Health Organization (WHO) guidelines. It also holds GMP certifications for formulations from Cambodia, Sudan, the Philippines, and Zimbabwe, along with a DNV certification for the export of medical device products.
• Ayushman Bharat is expected to drive volume growth in the healthcare sector, offering healthcare coverage of Rs 0.5 million per family (floater basis) to approximately 107.4 million families, with potential for greater reach as some states extend the scheme. As of June 2024, around 68.6 million treatments have been provided since the scheme’s inception in September 2018, with total claims of Rs 902 billion, reflecting an average treatment cost of Rs 13,146 per hospital admission.
• The company reported revenue from operations of Rs 274.71 crore in FY25, reflecting a marginal decline of 2% compared to Rs 280.34 crore in FY24. Profit after tax (PAT) increased significantly by 189% to Rs 10.5 crore in FY25 from Rs 3.63 crore in FY24, primarily driven by a reduction in expenses.
• The overall healthcare delivery market in India is projected to register a CAGR of approximately 9–11% between FY2024 and FY2029, reaching an estimated Rs 70–80 billion by FY2029, driven by sustained demand from end-use segments such as hospitals and clinics.

Trade AnyTime AnyWhere With Elite Empower Mobile App

 

Amanta Healthcare Limited IPO Risk Factors:

• The Company operates in a highly competitive industry, facing significant competition from both established and emerging players, including listed and unlisted entities such as Denis Chem Lab Limited, Cipla Ltd., Wockhardt Ltd., Mankind Pharma Ltd., Panacea Biotec Ltd, Sun pharma Industries, and Torrent Pharma. This competitive environment may exert pressure on pricing, margins, and market share, thereby posing a potential risk to the Company’s business performance.
• Fluctuations in the prices of key raw materials such as LDPE (Low Density Polyethylene) and PP granules (Polypropylene). The prices of LDPE and PP granules are volatile and largely linked to crude price volatility. Loss of these suppliers, or any fluctuation in the prices of these raw materials may have an adverse effect on it’s business, results of operations and financial conditions.
• Tariff-related issues pose a significant concern for the company, as exports to the United States are adversely affected, potentially impacting revenue, profitability, and the company’s competitive position in the U.S. market.

Amanta Healthcare Limited IPO Financial Performance:

Amanta Healthcare Limited IPO Shareholding Pattern:

Amanta Healthcare Limited IPO Outlook:

AHL is a pharmaceutical company engaged in developing, manufacturing, and marketing a wide portfolio of sterile liquid products. The company reported muted revenue from operations but delivered 189% growth in PAT, primarily driven by expense optimization. Its diverse generic product portfolio of over 45 products is marketed under its own brands across India through a robust distribution network of more than 320 distributors and stockists. As of March 31, 2025, the company achieved an impressive capacity utilization of 96%. Its manufacturing facility is certified for GMP, ensuring adherence to global quality standards. While industry growth is expected to benefit the company, challenges remain in terms of increasing competition, volatility in raw material prices, and tariff-related risks, any of which could adversely impact profitability. At the upper price band of Rs 126, the issue is valued at a P/E of 34.60x on a pre-IPO basis and 46.60x on a post-IPO basis, based on FY25 earnings. Considering the elevated valuations and the factors outlined, we recommend subscribing to the issue only for aggressive investors, primarily for potential listing gains and with a medium to long-term investment horizon.

Amanta Healthcare Limited IPO FAQ:

Ans. The finalization of Basis of Allotment for Amanta Healthcare IPO will be done on Thursday, September 4, 2025, and the allotted shares will be credited to your demat account by Monday, September 8, 2025.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 214

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Vindhyachal Prasad, Elite Wealth Limited, vindhyachal@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

• all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
• No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale. Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

• EWL or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
• EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

2. Compensation

• EWL or its associates have not received any compensation from the subject company in the past twelve months;
• EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
• EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
• EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
• EWL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research

3. In respect of Public Appearances

• EWL or its associates have not received any compensation from the subject company in the past twelve months;
• The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL